Skip to Main Content

Alexion Pharmaceuticals (ALXN) said Wednesday that it will acquire Achillion Pharmaceuticals to expand its pipeline of experimental drugs targeting rare diseases of the immune system.

The all-cash deal values Achillion at $930 million, or $6.30 per share, which represents a 72% premium over Achillion’s closing stock price on Tuesday. Achillion shareholders will also be offered a contingent value right worth another $2 per share, payable on the successful achievement of certain clinical and regulatory milestones.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!